What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 4 months ago
Nintedinib’s Durable Efficacy in Systemic Sclerosis
Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.
https://t.co/5M92Yhpeo1 https://t.co/qZvwfLs1jx
Dr. John Cush RheumNow
3 years 4 months ago
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/CbRQGzxJEr https://t.co/SlJNprUay3
Dr. John Cush RheumNow
3 years 4 months ago
New podcast—Dr.Cush answers your questions!
https://t.co/cif6yo0tGi https://t.co/kia5J0OMf6
Dr. John Cush RheumNow
3 years 4 months ago
Japanese SLE registry looked at infection risk with Prednisolone (PSL). Among 509 SLE pts (47 yrs); 77% used immunosuppressants & 52 had hospitalized infxns. Signif higher SIE w/ PSL 5.0–7.5 mg (aHR 6.8) & PSL 7.6-15 mg (aHR 7.6) vs 0-2.5 mg/d https://t.co/xZ5Yx4X1uw https://t.co/FSfsTENeUx
Dr. John Cush RheumNow
3 years 4 months ago
Study of 245 active SLE pts followed x 2 yrs shows low disease activity (LLDAS) achieved in 63%. By multivariate analysis, negative predictors of LLDAS were nephritis, heme involvement & low C3/C4. Early LLDAS predicted future LLDAS-50 https://t.co/IQaDFRtrZy https://t.co/G6MdBOMftX
Dr. John Cush RheumNow
3 years 4 months ago
TNR: Still's Now Journal Club - Pivotal Trials in SJIA & AOSD Approved Meds
This week's Stills disease Journal Club features expert panelists Drs. Olga Petryna, Daniel Lovell, Hermine Brunner and Jack Cush.
https://t.co/2TCtByJg4Q https://t.co/arqQUQJNNC
Dr. John Cush RheumNow
3 years 4 months ago
Rheumatic Causes for Fever of Unknown Origin
Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.
https://t.co/JXcp2k6hJ1 https://t.co/5i97sKde8n
Your patient doesn't meet criteria for Still’s disease (AOSD or sJIA), now what should you do or consider?
What you do or consider next can be addressed according to the stage of current disease: A) Hospitalized Febrile Disease, or B) Outpatient “Still’s” Disease.
Eric Topol EricTopol
3 years 4 months ago
I had the chance to discuss intrinsic protection from Covid with my friend @ASlavitt
https://t.co/dI993XBoXr https://t.co/lidQnzgjJg
Rheum Cat rheum_cat
3 years 4 months ago
Have the trends started to change in awards for more junior people in rheumatology? https://t.co/0UC9BvXfsY
Philosophy Pathfinder PhilosophyPath
3 years 4 months ago
15 Powerful Visuals About Psychology & Life
1. https://t.co/ZY6QwhA9bK
Rheum Cat rheum_cat
3 years 4 months ago
Our commentary on the SELECT-AXIS 2 trial is also available: https://t.co/dkB2h6OeKJ
@Spondy_MD https://t.co/GIDXVnhHcz
ARD & RMD Open ARD_BMJ
3 years 4 months ago
Get insights to difficult to treat rheumatoid arthritis #D2T from the experts👉 This report summarizes what we know and what we still need to know! https://t.co/Qdkcu0Z2sk https://t.co/FW5rvSK1vi
Dr. John Cush RheumNow
3 years 4 months ago
Best Labs for Still’s Disease
There is no “test” (blood or other) that is solely diagnostic of Still’s disease, but labs can help make a diagnosis or manage disease, and affirm the safety of drugs in use.
What tests should you be ordering?
https://t.co/24QSfEEVwG https://t.co/bdrvSBd652
Dr. John Cush RheumNow
3 years 4 months ago
The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list.
https://t.co/dC5vVEhCrC https://t.co/skXbg1fAve
Poster Hall